The Value of Routine Pharmacogenomic Screening – Are We There Yet?: A perspective on the costs and benefits of routine ADMET and HLA profiling – Shouldn’t everyone have this done?...

door Veenstra, David L.
Gepubliceerd in Clin Pharmacol Ther (2015)

Evolving research and stakeholder perspectives on pharmacogenomics

door Beitelshees, Amber L., Veenstra, David L.
Gepubliceerd in 2011

A FRAMEWORK FOR PRIORITIZING RESEARCH INVESTMENTS IN PRECISION MEDICINE

door Basu, Anirban, Carlson, Josh J., Veenstra, David L.
Gepubliceerd in Med Decis Making (2015)

Assessing the cost-effectiveness of pharmacogenomics

door Veenstra, David L., Higashi, Mitchell K., Phillips, Kathryn A.
Gepubliceerd in 2000

Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis

door Serbin, Michael A., Guzauskas, Gregory F., Veenstra, David L.
Gepubliceerd in J Manag Care Spec Pharm (2016)

Modeling the Cost and Outcomes of Pharmacist-Prescribed Emergency Contraception

door Marciante, Kristin D., Gardner, Jacqueline S., Veenstra, David L., Sullivan, Sean D.
Gepubliceerd in 2001

The Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting

door Hart, Ragan, Veenstra, David L., Boudreau, Denise M., Roth, Joshua A.
Gepubliceerd in Am J Med (2016)

Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment

door Weymann, Deirdre, Veenstra, David L., Jarvik, Gail P., Regier, Dean A.
Gepubliceerd in Eur J Hum Genet (2018)

CDR State Transition Probabilities in Alzheimer's Disease with and without Cholinesterase Inhibitor Intervention in an Observational Cohort

door Bloudek, Lisa M., Spackman, D. Eldon, Veenstra, David L., Sullivan, Sean D.
Gepubliceerd in 2011

Artificial intelligence in breast cancer screening: primary care provider preferences

door Hendrix, Nathaniel, Hauber, Brett, Lee, Christoph I, Bansal, Aasthaa, Veenstra, David L
Gepubliceerd in J Am Med Inform Assoc (2020)

Paying for personalized care: Cancer biomarkers and comparative effectiveness

door Thariani, Rahber, Veenstra, David L., Carlson, Josh J., Garrison, Louis P., Ramsey, Scott
Gepubliceerd in 2012

Long-term Survival in Patients with Severe Acute Respiratory Distress Syndrome and Rescue Therapies for Refractory Hypoxemia

door Khandelwal, Nita, Hough, Catherine L., Bansal, Aasthaa, Veenstra, David L., Treggiari, Miriam M.
Gepubliceerd in 2014

The cost-effectiveness of returning incidental findings from next-generation genomic sequencing

door Bennette, Caroline S., Gallego, Carlos J., Burke, Wylie, Jarvik, Gail P., Veenstra, David L.
Gepubliceerd in Genet Med (2014)

Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting

door Roth, Joshua A., Bradley, Katharine, Thummel, Kenneth E., Veenstra, David L., Boudreau, Denise
Gepubliceerd in Pharmacoepidemiol Drug Saf (2015)

Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities

door Conti, Rena, Veenstra, David L., Armstrong, Katrina, Lesko, Lawrence J., Grosse, Scott D.
Gepubliceerd in Med Decis Making (2010)

Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy

door Dhanda, Devender S., Guzauskas, Gregory F., Carlson, Josh J., Basu, Anirban, Veenstra, David L.
Gepubliceerd in Clin Pharmacol Ther (2017)

Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy

door Guzauskas, Gregory F., Basu, Anirban, Serbin, Michael, Carlson, Josh J., Veenstra, David L.
Gepubliceerd in Value Health (2019)

Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support

door Hoath James I, Tarczy-Hornoch Peter, Overby Casey, Kalet Ira J, Veenstra David L
Gepubliceerd in 2010-10-01

A Formal Risk-Benefit Framework for Genomic Tests: Facilitating the Appropriate Translation of Genomics Into Clinical Practice

door Veenstra, David L., Roth, Joshua A., Garrison, Louis P., Ramsey, Scott D., Burke, Wylie
Gepubliceerd in 2010

The Value of Comparative Effectiveness Research: Projected Return on Investment of the RxPONDER Trial (SWOG S1007)

door Wong, William, Ramsey, Scott D., Barlow, William E., Garrison, Louis P., Veenstra, David L.
Gepubliceerd in 2012